AbCellera

Update in progress

ABCL (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

AbCellera Biologics discovers and develops antibody-based medicines for unmet medical needs in the United States. Its lead candidate, ABCL635, is a non-hormonal therapy in Phase 2 for moderate-to-severe vasomotor symptoms. ABCL575 is a fully human, half-life–extended monoclonal antibody in Phase 1 for T-cell–mediated autoimmune conditions such as atopic dermatitis. The company collaborates with Eli Lilly, AbbVie, Biogen, Viking Global and ArrowMark. Founded 2012, based in Vancouver.

Company score

Sentiment: 0.35; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive